IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 224 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,431,367 | -44.9% | 11,962,938 | -14.8% | 1.82% | -36.5% |
| Q2 2023 | $98,816,326 | +5.4% | 14,036,410 | -8.5% | 2.86% | +3.4% |
| Q1 2023 | $93,725,780 | +47.1% | 15,339,735 | +53.8% | 2.77% | +54.7% |
| Q4 2022 | $63,719,674 | -35.1% | 9,971,780 | -2.7% | 1.79% | -37.2% |
| Q3 2022 | $98,181,000 | -24.8% | 10,248,624 | -13.3% | 2.85% | -30.3% |
| Q2 2022 | $130,562,000 | -35.7% | 11,826,299 | -3.1% | 4.09% | +0.5% |
| Q1 2022 | $203,150,000 | -47.5% | 12,201,261 | -39.8% | 4.07% | +36.5% |
| Q4 2021 | $386,684,000 | +36.5% | 20,255,882 | +76.3% | 2.98% | -27.6% |
| Q3 2021 | $283,337,000 | -50.3% | 11,489,772 | -47.6% | 4.12% | +11.1% |
| Q2 2021 | $570,346,000 | +108.2% | 21,919,544 | +153.4% | 3.70% | +6.9% |
| Q1 2021 | $273,915,000 | -35.6% | 8,651,785 | -5.6% | 3.46% | -24.1% |
| Q4 2020 | $425,316,000 | +28.1% | 9,166,304 | -9.1% | 4.56% | -5.8% |
| Q3 2020 | $332,019,000 | +2.4% | 10,085,632 | -14.6% | 4.85% | -7.7% |
| Q2 2020 | $324,170,000 | -7.2% | 11,809,494 | +1.2% | 5.25% | -42.3% |
| Q1 2020 | $349,343,000 | +34.0% | 11,670,057 | +23.9% | 9.10% | +75.8% |
| Q4 2019 | $260,640,000 | +30.0% | 9,416,202 | -14.5% | 5.18% | -4.1% |
| Q3 2019 | $200,467,000 | -31.4% | 11,014,702 | -7.6% | 5.40% | -19.4% |
| Q2 2019 | $292,158,000 | +151.1% | 11,915,127 | -2.6% | 6.70% | +104.2% |
| Q1 2019 | $116,362,000 | +7.4% | 12,235,811 | -0.0% | 3.28% | -20.4% |
| Q4 2018 | $108,333,000 | +32.1% | 12,241,111 | +67.9% | 4.12% | +88.0% |
| Q3 2018 | $82,014,000 | +9.5% | 7,290,199 | +24.6% | 2.19% | +11.7% |
| Q2 2018 | $74,908,000 | -28.1% | 5,852,202 | -5.0% | 1.96% | -32.7% |
| Q1 2018 | $104,141,000 | +172.6% | 6,162,202 | +29.0% | 2.92% | +130.2% |
| Q4 2017 | $38,208,000 | -47.8% | 4,776,114 | -49.5% | 1.27% | -9.4% |
| Q3 2017 | $73,254,000 | +128.4% | 9,452,228 | +116.6% | 1.40% | -13.3% |
| Q2 2017 | $32,068,000 | – | 4,363,114 | – | 1.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |